How have the shares performed?
Orphazyme A/S (ORPH) saw downtrend of -55.57% in the recent trading with $9.33 being its most recent. The current price level -88.00% lower than the highest price of $77.77 marked by the stock while trading over the past 52-weeks, whereas it is 96.42% higher than the lowest price of $4.75 the company dropped to over past 52-weeks. The latest news story on ORPH appeared in Bloomberg under the title “The New Meme Stock Is a Danish Biotech Firm That Spiked 1,387%” on Jun-11-21.
Squeezing the time span to 30 day period shows us the stock is currently trading -88.00% below one month high and is +96.42% above of the lowest during that time. Looking into the simple moving average, Orphazyme A/S (ORPH)’s stock stands at a SMA-50 of $7.80 while that of 5-day is reading $9.24.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Hold by 4 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 3.00 for the stock.
Orphazyme A/S Earnings – What Happened With ORPH
Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
ORPH – Orphazyme A/S Stock Earnings Estimates
1 analysts covering the stock at Wall Street were agreed upon that EPS consensus.
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 34.95 million. ORPH does have institutional investors; and they hold 0.50% of the stock.
Orphazyme A/S – Insider Activity and Holdings
As on Mar 30, 2021, Point72 Asset Management, L.P. was the top most holder in Orphazyme A/S (NASDAQ:ORPH) with an ownership of 0.13 million shares of the company or 0.38% of the stake worth $1.12 million. The filing also reveals Millennium Management LLC as the second largest holder in the company with a control over 0.35% of the outstanding shares. Its stake is worth $1.02 million for having 0.12 million shares in hand.
Caas Capital Management LP also came holding a key position in the company during the recent quarter and it now holds 0.06% of the outstanding shares. With this there are now 9 institutions which have possession in ORPH’s shares.
Currently, the stock has been recommended as Hold by 4 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 3.00 for the stock.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. The count was 5.43 for long-term debt to equity ratio.